The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST).
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Victoria S. Chua-Alcala
No Relationships to Disclose
 
Jasgit C. Sachdev
Honoraria - AstraZeneca; Celgene; Immunomedics; Ipsen; Novartis; Pfizer; Puma Biotechnology; Tempus
Consulting or Advisory Role - Celgene
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Celgene
 
David S. Wages
Stock and Other Ownership Interests - iSpecimen
Consulting or Advisory Role - Acerta Pharma/AstraZeneca; Fujifilm; IQvia; Myovant Sciences; Salarius Pharmaceuticals
 
David D. Stenehjem
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb; Dracen; Iterion Therapeutics; Molecular Templates; Salarius Pharmaceuticals
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bioverativ (Inst); Bristol-Myers Squibb (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Daniela Y. Santiesteban
Employment - Salarius Pharmaceuticals
Stock and Other Ownership Interests - Salarius Pharmaceuticals; Salarius Pharmaceuticals (I)
 
Nadeem Q. Mirza
Employment - Salarius Pharmaceuticals; Verastem
Stock and Other Ownership Interests - Salarius Pharmaceuticals
 
Michael S. Gordon
Stock and Other Ownership Interests - BeckonCall; Caremission; WCCT Global
Consulting or Advisory Role - Agenus; Castle Biosciences; Daiichi Sankyo; Deciphera; Imaging Endpoints; Neon Therapeutics; RedHill Biopharma; Salarius Pharmaceuticals; TRACON Pharma
Research Funding - AADi (Inst); Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Aduro Biotech (Inst); Advaxis (Inst); Agenus (Inst); Amal Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); BeiGene (Inst); Beigene (Inst); BiolineRx (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); CanBas (Inst); cantex (Inst); Caris Centers of Excellence (Inst); Celgene (Inst); Celldex (Inst); Corcept Therapeutics (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Driver Group (Inst); Endocyte (Inst); ESSA (Inst); FibroGen (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Genentech/Roche (Inst); Genocea Biosciences (Inst); Genzada Pharmaceuticals (Inst); Genzada Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Helix BioPharma (Inst); Hengrui Therapeutics (Inst); IgM Biosciences (Inst); ImaginAb (Inst); ImmuneSensor Therapeutics (Inst); Inanovate (Inst); Incyte (Inst); Inhibrx (Inst); Lilly (Inst); Lilly/ImClone (Inst); MabVax (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Millennium (Inst); Minneamrita Therapeutics (Inst); Molecular Partners (Inst); Nektar (Inst); Nektar (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Revolution Medicines (Inst); Salarius Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Sirtex Medical (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Syndax (Inst); SynDevRx (Inst); Syros Pharmaceuticals (Inst); tesaro (Inst); Tokai Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); TRACON Pharma (Inst); Trovagene (Inst); TTC Oncology (Inst); Verastem (Inst); Veru (Inst)
Patents, Royalties, Other Intellectual Property - Patient on patient selection for Clinical Trials